Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab-Reference-Cited by-同舟云学术

Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab

Published:2022-09-09 Issue:1 Volume:17 Page:86-96
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Hatanaka Takeshi^ORCID,Kakizaki Satoru^ORCID,Hiraoka Atsushi^ORCID,Tada Toshifumi^ORCID,Hirooka Masashi,Kariyama Kazuya,Tani Joji,Atsukawa Masanori,Takaguchi Koichi,Itobayashi Ei,Fukunishi Shinya,Tsuji Kunihiko,Ishikawa Toru^ORCID,Tajiri Kazuto^ORCID,Ochi Hironori,Yasuda Satoshi,Toyoda Hidenori^ORCID,Ogawa Chikara,Nishimura Takashi^ORCID,Shimada Noritomo,Kawata Kazuhito^ORCID,Kosaka Hisashi^ORCID,Tanaka Takaaki,Ohama Hideko,Nouso Kazuhiro,Morishita Asahiro^ORCID,Tsutsui Akemi,Nagano Takuya,Itokawa Norio,Okubo Tomomi,Arai Taeang,Imai Michitaka,Naganuma Atsushi^ORCID,Koizumi Yohei,Nakamura Shinichiro,Kaibori Masaki^ORCID,Iijima Hiroko^ORCID,Hiasa Yoichi^ORCID,Kumada Takashi^ORCID,

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

https://link.springer.com/content/pdf/10.1007/s12072-022-10406-8.pdf

Reference42 articles.

1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894–1905

2. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163–1173

3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390

4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34

5. Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, et al. Trial design and endpoints in hepatocellular carcinoma: AASLD Consensus Conference. Hepatology 2021;73(Suppl 1):158–191

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis;Liver Cancer;2024-05-22

2. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial;Alimentary Pharmacology & Therapeutics;2024-05-08

3. A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma;Clinical Cancer Research;2024-04-19

4. Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis;BioScience Trends;2024-02-29

5. Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System;Clinical Drug Investigation;2024-02-01